|
000
| 01830nam 2200325za 4500 |
|---|
| 001 | 9.856559 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107155547 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 180514s2018 onc #ob f000 0 eng d |
|---|
| 020 | |a978-0-660-26580-3 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH164-236/2018E-PDF |
|---|
| 245 | 00|aSubmission of targeted risk management plans and follow-up commitments for prescription opioid-containing products |h[electronic resource] : |bguidance for industry. |
|---|
| 246 | 10|aGuidance for industry |
|---|
| 260 | |aOttawa : |bHealth Canada, |c2018. |
|---|
| 300 | |aiii, 23 p. |
|---|
| 500 | |a"Effective date May 2, 2018." |
|---|
| 500 | |aTitle from cover. |
|---|
| 500 | |a"Your health and safety ... our priority." |
|---|
| 500 | |aIssued also in French under title: Présentation des plans de gestion des risques ciblés et des engagements de suivi pour les produits sur ordonnance à base d’opioïdes : document d’orientation à l’intention de l’industrie. |
|---|
| 504 | |aIncludes bibliographical references. |
|---|
| 520 | |a"Opioids are regulated under the Food and Drugs Act and the Controlled Drugs and Substances Act. A majority of the marketed prescription opioid products are used to treat pain, but some are also used to control moderate to severe cough, to control diarrhea, as anesthetics, and to treat opioid use disorder"--Introduction, p. 1. |
|---|
| 692 | 07|2gccst|aPrescription drugs |
|---|
| 692 | 07|2gccst|aRisk management |
|---|
| 692 | 07|2gccst|aIndustrial policy |
|---|
| 710 | 1 |aCanada. |bHealth Canada. |
|---|
| 775 | 08|tPrésentation des plans de gestion des risques ciblés et des engagements de suivi pour les produits sur ordonnance à base d’opioïdes |w(CaOODSP)9.856560 |
|---|
| 856 | 40|qPDF|s836 KB|uhttps://publications.gc.ca/collections/collection_2018/sc-hc/H164-236-2018-eng.pdf |
|---|